$VRDN
Viridian Therapeutics, Inc.\DE

2018 Q1 Form 10-K Financial Statement

#000159075018000006 Filed on March 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q3
Revenue $4.784M $1.192M $1.631M
YoY Change 935.5% 134.18% 74.25%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.990M $2.550M $2.500M
YoY Change -8.84% 1.19% 3.05%
% of Gross Profit
Research & Development $6.413M $4.998M $5.018M
YoY Change 55.66% 27.96% 69.24%
% of Gross Profit
Depreciation & Amortization $69.00K $80.00K $100.0K
YoY Change -31.0% -60.0% 0.0%
% of Gross Profit
Operating Expenses $9.403M $4.998M $7.520M
YoY Change 27.05% 27.96% 49.86%
Operating Profit -$4.619M -$5.889M
YoY Change -33.43% 44.27%
Interest Expense -$40.00K -$30.00K $60.00K
YoY Change 0.0% -50.0% 160.87%
% of Operating Profit
Other Income/Expense, Net $167.0K -$32.00K $113.0K
YoY Change 456.67% -46.67% 1514.29%
Pretax Income -$4.660M -$6.390M -$5.830M
YoY Change -33.24% 7.04% 40.48%
Income Tax
% Of Pretax Income
Net Earnings -$4.661M -$6.386M -$5.834M
YoY Change -33.22% 6.9% 40.48%
Net Earnings / Revenue -97.43% -535.74% -357.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.633M -$4.289M -$4.049M
COMMON SHARES
Basic Shares Outstanding 30.17M shares 22.31M shares 21.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.10M $47.40M $42.80M
YoY Change 43.83% 114.48% 692.59%
Cash & Equivalents $78.10M $47.44M $42.81M
Short-Term Investments
Other Short-Term Assets $3.400M $3.000M $3.000M
YoY Change 41.67% 66.67% 650.0%
Inventory
Prepaid Expenses
Receivables $4.809M $1.456M $635.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $86.35M $51.87M $46.42M
YoY Change 51.66% 117.23% 612.85%
LONG-TERM ASSETS
Property, Plant & Equipment $589.0K $563.0K $610.0K
YoY Change -1.34% -9.92% -39.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.00K $50.00K $50.00K
YoY Change -80.62% -80.62%
Total Long-Term Assets $639.0K $613.0K $660.0K
YoY Change -25.26% -30.58% -35.86%
TOTAL ASSETS
Total Short-Term Assets $86.35M $51.87M $46.42M
Total Long-Term Assets $639.0K $613.0K $660.0K
Total Assets $86.99M $52.48M $47.08M
YoY Change 50.52% 111.96% 524.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $760.0K $906.0K $409.0K
YoY Change -32.44% -10.03% 701.96%
Accrued Expenses $3.377M $2.991M $4.142M
YoY Change -19.21% -23.48% 151.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $2.000M
YoY Change -100.0%
Total Short-Term Liabilities $4.137M $3.897M $6.534M
YoY Change -43.17% -43.4% 129.02%
LONG-TERM LIABILITIES
Long-Term Debt $10.00M $9.900M $1.400M
YoY Change 334.78% 253.57%
Other Long-Term Liabilities $131.0K $152.0K $171.0K
YoY Change -24.71% 8450.0%
Total Long-Term Liabilities $131.0K $152.0K $171.0K
YoY Change -24.71% 8450.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.137M $3.897M $6.534M
Total Long-Term Liabilities $131.0K $152.0K $171.0K
Total Liabilities $14.29M $13.97M $8.096M
YoY Change 45.78% 43.96% 183.57%
SHAREHOLDERS EQUITY
Retained Earnings -$98.25M -$93.59M -$87.21M
YoY Change 32.67% 39.53% 247.83%
Common Stock $302.0K $226.0K $219.0K
YoY Change 41.12% 2725.0% 102.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.71M $38.51M $38.99M
YoY Change
Total Liabilities & Shareholders Equity $86.99M $52.48M $47.08M
YoY Change 50.52% 111.96% 524.33%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.661M -$6.386M -$5.834M
YoY Change -33.22% 6.9% 40.48%
Depreciation, Depletion And Amortization $69.00K $80.00K $100.0K
YoY Change -31.0% -60.0% 0.0%
Cash From Operating Activities -$7.361M -$7.250M -$5.660M
YoY Change -10.05% -22.95% 405.36%
INVESTING ACTIVITIES
Capital Expenditures $95.00K -$40.00K -$60.00K
YoY Change 115.91% -84.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$95.00K -$40.00K -$60.00K
YoY Change -107.69% -84.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $38.11M 11.91M 2.200M
YoY Change -2.56% -25.52% -11100.0%
NET CHANGE
Cash From Operating Activities -$7.361M -7.250M -5.660M
Cash From Investing Activities -$95.00K -40.00K -60.00K
Cash From Financing Activities $38.11M 11.91M 2.200M
Net Change In Cash $30.66M 4.620M -3.520M
YoY Change -4.7% -27.01% 208.77%
FREE CASH FLOW
Cash From Operating Activities -$7.361M -$7.250M -$5.660M
Capital Expenditures $95.00K -$40.00K -$60.00K
Free Cash Flow -$7.456M -$7.210M -$5.600M
YoY Change -9.37% -21.29% 400.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001590750
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30172086 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
122400000 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
MIRAGEN THERAPEUTICS, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 mgen Accretionof Offering Costs
AccretionofOfferingCosts
49000 USD
CY2017 mgen Accretionof Offering Costs
AccretionofOfferingCosts
5000 USD
CY2016Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
759000 USD
CY2017Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
185000 USD
CY2016Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
0 USD
CY2017Q4 mgen Accrued Liabilities Equipmentand Lab Materials
AccruedLiabilitiesEquipmentandLabMaterials
197000 USD
CY2016Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
133000 USD
CY2017Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
82000 USD
CY2016Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
1684000 USD
CY2017Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
581000 USD
CY2017Q4 mgen Accumulated Amortization Deferred Costs
AccumulatedAmortizationDeferredCosts
23000 USD
CY2017 mgen Adjustmentsto Additional Paidin Capital Reclassificationof Warrant Liability
AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability
51000 USD
CY2017Q4 mgen Capital Stock Shares Authorized
CapitalStockSharesAuthorized
105000000 shares
CY2016 mgen Conversionof Warrantsto Permanent Equity
ConversionofWarrantstoPermanentEquity
0 USD
CY2017 mgen Conversionof Warrantsto Permanent Equity
ConversionofWarrantstoPermanentEquity
51000 USD
CY2016 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2017 mgen Deferred Tax Asset Valuation Allowance Percent
DeferredTaxAssetValuationAllowancePercent
1
CY2016Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
1414000 USD
CY2017Q4 mgen Deferred Tax Assets Tax Deferred Expense Startup Costs
DeferredTaxAssetsTaxDeferredExpenseStartupCosts
829000 USD
CY2016 mgen Effective Income Tax Rate Reconciliation Reduction In Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationReductionInNetOperatingLossPercent
0.000
CY2017 mgen Effective Income Tax Rate Reconciliation Reduction In Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationReductionInNetOperatingLossPercent
0.067
CY2016Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
167000 USD
CY2017Q4 mgen Long Term Debt Accumulated Accretion Of Final Payment Fee
LongTermDebtAccumulatedAccretionOfFinalPaymentFee
41000 USD
CY2016 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2017 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
300000 USD
CY2016 mgen Paymentsfor Debt Issuance Costs Notes Payable
PaymentsforDebtIssuanceCostsNotesPayable
6000 USD
CY2017 mgen Paymentsfor Debt Issuance Costs Notes Payable
PaymentsforDebtIssuanceCostsNotesPayable
0 USD
CY2017 mgen Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding
0.04
CY2017Q4 mgen Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding
SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding
940298 shares
CY2017 mgen Tax Credit Carryforward Limitations On Use Amount
TaxCreditCarryforwardLimitationsOnUseAmount
4600000 USD
CY2017 mgen Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
10800000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1007000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
906000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1456000 USD
CY2016 us-gaap Accretion Expense
AccretionExpense
158000 USD
CY2017 us-gaap Accretion Expense
AccretionExpense
94000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3909000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2991000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
124000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
232000 USD
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
221000 USD
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
74000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2558000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2835000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5147000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131877000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
198000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
400000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
127000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
198000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2409000 USD
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15421000 shares
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2912000 shares
CY2016Q4 us-gaap Assets
Assets
24760000 USD
CY2017Q4 us-gaap Assets
Assets
52481000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
23877000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
51868000 USD
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1280000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21235000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22104000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47441000 USD
CY2016 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
869000 USD
CY2017 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
25337000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
742058 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
833744 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22568006 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
833744 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22568006 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
226000 USD
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4667000 USD
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
14000 USD
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
119000 USD
CY2016Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
31000 USD
CY2017Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
0 USD
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
200000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26342000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22509000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20961000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18257000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2785000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2287000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
439000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1182000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
697000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26342000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22509000 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
341000 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
308000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.58
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.88
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.92
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.20
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-28.21
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.38
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.430
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.145
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.407
CY2016 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.029
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.019
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.006
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.052
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.048
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
928000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1538000 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7000000 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y0M0D
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
169000 USD
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3000 USD
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2016 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
3000 USD
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
39000 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
133000 USD
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-51000 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
82000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
992000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1210000 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2053000 USD
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2517000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6772000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3281000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2581000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2502000 USD
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2548000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10912000 USD
CY2016Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2016Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2017Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
292000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-101000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1436000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2211000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2205000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-519000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
426000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
724000 USD
CY2016 us-gaap Interest And Debt Expense
InterestAndDebtExpense
326000 USD
CY2017 us-gaap Interest And Debt Expense
InterestAndDebtExpense
383000 USD
CY2016 us-gaap Interest Paid
InterestPaid
164000 USD
CY2017 us-gaap Interest Paid
InterestPaid
446000 USD
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
281000 USD
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
9705000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
13971000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24760000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52481000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6885000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3897000 USD
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2814000 USD
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3097000 USD
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
10000000 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
3667000 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2333000 USD
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2820000 USD
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9922000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15874000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52470000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-250000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1034000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14755000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28167000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3623000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3524000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4153000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-5974000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-17274000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6980000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-7312000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5834000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6386000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-26512000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3635000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3536000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4166000 USD
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5986000 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17323000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6985000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7312000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5834000 USD
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6386000 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26517000 USD
CY2016 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
0 USD
CY2017 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1076000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
39000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
403000 USD
CY2016Q4 us-gaap Notes Payable
NotesPayable
4789000 USD
CY2017Q4 us-gaap Notes Payable
NotesPayable
9922000 USD
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1969000 USD
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2016 us-gaap Operating Expenses
OperatingExpenses
20464000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
30535000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-16987000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-26532000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1072000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
391000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2971000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
277000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
404000 USD
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
73200000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
60000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
102000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
258000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-71000 USD
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-60000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
55000 USD
CY2017Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-32000 USD
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1500000 USD
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1000000 USD
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
250000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
246000 USD
CY2016 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
49000 USD
CY2017 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
5000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1753000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40700000 USD
CY2016 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
16091000 USD
CY2017 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0 USD
CY2016 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000000 USD
CY2016 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
0 USD
CY2017 us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
110000 USD
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1000000 USD
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
213000 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
307000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
300000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3183000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3398000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
625000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
563000 USD
CY2016 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
0 USD
CY2017 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
76981000 USD
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
333000 USD
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4667000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
718000 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1631000 USD
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
1192000 USD
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
4003000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
204000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
281000 USD
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
213000 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
307000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
198000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2409000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
902720 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4182404 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3800000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3466000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3355000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2965000 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3906000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13692000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4120000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5487000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5018000 USD
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4998000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19623000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67076000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93593000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
663000 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
906000 USD
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
917000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1115000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
936000 USD
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
509000 USD
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
3477000 USD
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
462000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-45290000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-61921000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
38510000 USD
CY2016 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
49000 USD
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
5000 USD
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7400000 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3800000 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
614017 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19244605 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S.&#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001590750-18-000006-index-headers.html Edgar Link pending
0001590750-18-000006-index.html Edgar Link pending
0001590750-18-000006.txt Edgar Link pending
0001590750-18-000006-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mgen-12312017x10k.htm Edgar Link pending
mgen-12312017xex211.htm Edgar Link pending
mgen-12312017xex231.htm Edgar Link pending
mgen-12312017xex311.htm Edgar Link pending
mgen-12312017xex312.htm Edgar Link pending
mgen-12312017xex321.htm Edgar Link pending
mgen-12312017xex42new.htm Edgar Link pending
mgen-20171231.xml Edgar Link completed
mgen-20171231.xsd Edgar Link pending
mgen-20171231_cal.xml Edgar Link unprocessable
mgen-20171231_def.xml Edgar Link unprocessable
mgen-20171231_lab.xml Edgar Link unprocessable
mgen-20171231_pre.xml Edgar Link unprocessable
partbmswat3.jpg Edgar Link pending
productcandidates4a01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending